Relapsing Multiple Sclerosis (RMS)

Also known as: Relapsing multiple sclerosis (MS) / Multiple Sclerosis Relapse / Relapsed Multiple sclerosis / Relapsing Multiple Sclerosis / Multiple sclerosis flare

Drug	Drug Name	Drug Description
DB00242	Cladribine	A purine antimetabolite used for the management of relapsing forms of Multiple Sclerosis (MS), used in patients who have not responded to or who were unable to tolerate alternative MS drugs.
DB00111	Daclizumab	A monoclonal anti-CD25 antibody that blocks the interleukin-2 receptor which is used to treat relapsing forms of multiple sclerosis.
DB14783	Diroximel fumarate	A drug used for the treatment of relapsing forms of Multiple Sclerosis (MS).
DB08868	Fingolimod	A sphingosine 1-phosphate receptor modulator used to treat patients with the relapsing-remitting form of multiple sclerosis (MS) and studied to manage lung complications of COVID-19.
DB11988	Ocrelizumab	A CD20 specific monoclonal antibody used to treat relapsing remitting multiple sclerosis.
DB06650	Ofatumumab	An anti-CD20 antibody used for the treatment of chronic lymphocytic leukemia (CLL) in selected patients with certain treatment histories and responsiveness to anticancer medications.
DB09122	Peginterferon beta-1a	An interferon beta used to treat relapsing forms of multiple sclerosis.
DB12371	Siponimod	A medication used to treat relapsing multiple sclerosis.

Drug	Drug Name	Target	Type
DB00242	Cladribine	Purine nucleoside phosphorylase	target
DB00242	Cladribine	DNA	target
DB00242	Cladribine	Deoxycytidine kinase	enzyme
DB00242	Cladribine	Ribonucleoside-diphosphate reductase large subunit	target
DB00242	Cladribine	Ribonucleoside-diphosphate reductase subunit M2	target
DB00242	Cladribine	Ribonucleoside-diphosphate reductase subunit M2 B	target
DB00242	Cladribine	DNA polymerase alpha catalytic subunit	target
DB00242	Cladribine	DNA polymerase epsilon catalytic subunit A	target
DB00242	Cladribine	DNA polymerase epsilon subunit 2	target
DB00242	Cladribine	DNA polymerase epsilon subunit 3	target
DB00242	Cladribine	DNA polymerase epsilon subunit 4	target
DB00242	Cladribine	ATP-binding cassette sub-family G member 2	transporter
DB00242	Cladribine	Solute carrier family 28 member 3	transporter
DB00111	Daclizumab	Interleukin-2 receptor subunit alpha	target
DB00111	Daclizumab	Low affinity immunoglobulin gamma Fc region receptor III-B	target
DB00111	Daclizumab	Complement C1r subcomponent	target
DB00111	Daclizumab	Complement C1q subcomponent subunit A	target
DB00111	Daclizumab	Complement C1q subcomponent subunit B	target
DB00111	Daclizumab	Complement C1q subcomponent subunit C	target
DB00111	Daclizumab	Low affinity immunoglobulin gamma Fc region receptor III-A	target
DB00111	Daclizumab	High affinity immunoglobulin gamma Fc receptor I	target
DB00111	Daclizumab	Low affinity immunoglobulin gamma Fc region receptor II-a	target
DB00111	Daclizumab	Interleukin-2 receptor subunit beta	target
DB00111	Daclizumab	Low affinity immunoglobulin gamma Fc region receptor II-b	target
DB00111	Daclizumab	Low affinity immunoglobulin gamma Fc region receptor II-c	target
DB14783	Diroximel fumarate	Liver esterases	enzyme
DB14783	Diroximel fumarate	Neuronal acetylcholine receptor subunit alpha-10	target
DB08868	Fingolimod	Sphingosine 1-phosphate receptor 5	target
DB08868	Fingolimod	Sphingosine kinase 1	enzyme
DB08868	Fingolimod	Cytochrome P450 2E1	enzyme
DB08868	Fingolimod	Leukotriene-B(4) omega-hydroxylase 1	enzyme
DB08868	Fingolimod	Histone deacetylase 1	target
DB08868	Fingolimod	Excitatory amino acid transporter 2	transporter
DB08868	Fingolimod	Excitatory amino acid transporter 1	transporter
DB08868	Fingolimod	P-glycoprotein 1	transporter
DB08868	Fingolimod	Multidrug resistance-associated protein 1	transporter
DB08868	Fingolimod	Sphingosine 1-phosphate receptor 1	target
DB08868	Fingolimod	Sphingosine 1-phosphate receptor 4	target
DB08868	Fingolimod	Sphingosine 1-phosphate receptor 3	target
DB11988	Ocrelizumab	B-lymphocyte antigen CD20	target
DB06650	Ofatumumab	B-lymphocyte antigen CD20	target
DB09122	Peginterferon beta-1a	Cytochrome P450 1A2	enzyme
DB09122	Peginterferon beta-1a	Interferon alpha/beta receptor 1	target
DB12371	Siponimod	Sphingosine 1-phosphate receptor 5	target
DB12371	Siponimod	Sphingosine 1-phosphate receptor 1	target
DB12371	Siponimod	Cytochrome P450 3A4	enzyme
DB12371	Siponimod	Cytochrome P450 2C9	enzyme

Drug	Drug Name	Phase	Status	Count
DB00242	Cladribine	1	Recruiting	2
DB00977	Ethinylestradiol	1	Recruiting	2
DB00367	Levonorgestrel	1	Recruiting	2
DB05092	CDP323	1 / 2	Completed	1
DB06399	Atacicept	2	Terminated	2
DB05259	Glatiramer	2	Not Yet Recruiting	1
DB00060	Interferon beta-1a	2	Not Yet Recruiting	1
DB00068	Interferon beta-1b	2	Not Yet Recruiting	1
DB06685	Laquinimod	2	Withdrawn	1
DB00108	Natalizumab	2	Terminated	1
DB06650	Ofatumumab	2	Completed	1
DB09122	Peginterferon beta-1a	2	Not Yet Recruiting	1
DB09145	Water	2	Not Yet Recruiting	1
DB00087	Alemtuzumab	3	Recruiting	1
DB00242	Cladribine	3	Recruiting	1
DB10583	Clostridium tetani toxoid antigen (formaldehyde inactivated)	3	Completed	1
DB10583	Clostridium tetani toxoid antigen (formaldehyde inactivated)	3	Recruiting	1
DB15170	Evobrutinib	3	Recruiting	2
DB14785	Fenebrutinib	3	Recruiting	2
DB08868	Fingolimod	3	Completed	2
DB14999	Human interferon beta	3	Terminated	1
DB01050	Ibuprofen	3	Completed	1
DB00060	Interferon beta-1a	3	Active Not Recruiting	2
DB00060	Interferon beta-1a	3	Completed	5
DB05299	Keyhole limpet hemocyanin	3	Recruiting	1
DB06685	Laquinimod	3	Terminated	2
DB00788	Naproxen	3	Completed	1
DB00108	Natalizumab	3	Recruiting	1
DB11988	Ocrelizumab	3	Active Not Recruiting	2
DB11988	Ocrelizumab	3	Recruiting	1
DB06650	Ofatumumab	3	Completed	1
DB06650	Ofatumumab	3	Not Yet Recruiting	1
DB06650	Ofatumumab	3	Recruiting	3
DB09122	Peginterferon beta-1a	3	Completed	3
DB00073	Rituximab	3	Recruiting	2
DB08880	Teriflunomide	3	Completed	3
DB08880	Teriflunomide	3	Recruiting	6
DB08880	Teriflunomide	3	Terminated	1
DB11850	Ublituximab	3	Completed	2
DB11850	Ublituximab	3	Enrolling by Invitation	1
DB08868	Fingolimod	4	Completed	1
DB08868	Fingolimod	4	Recruiting	1
DB14999	Human interferon beta	4	Withdrawn	1
DB00060	Interferon beta-1a	4	Completed	1
DB00060	Interferon beta-1a	4	Withdrawn	1
DB00068	Interferon beta-1b	4	Withdrawn	1
DB00108	Natalizumab	4	Terminated	1
DB11988	Ocrelizumab	4	Not Yet Recruiting	1
DB11988	Ocrelizumab	4	Recruiting	1
DB06650	Ofatumumab	4	Recruiting	1
DB09122	Peginterferon beta-1a	4	Withdrawn	1
DB08880	Teriflunomide	4	Recruiting	1
DB00060	Interferon beta-1a	Not Available	Completed	2
DB00108	Natalizumab	Not Available	Completed	1